Calistoga Pharmaceuticals’ CAL-101, an Oral Delta Isoform-Selective PI3K Inhibitor, Demonstrates Clinical Benefit in Patients with Relapsed or Refractory Indolent Non Hodgkin’s Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

SEATTLE--(BUSINESS WIRE)--Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today presented updated clinical data on CAL-101, the Company’s oral, delta selective PI3K inhibitor, demonstrating anti-tumor activity in patients with hematologic malignancies treated during a Phase 1 clinical trial. Data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.